Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EZH2 Y646N||melanoma||sensitive||EZH2 inhibitor||GSK126||Preclinical - Cell culture||Actionable||In a preclinical study, GSK126 treatment inhibited cell growth via suppression of downstream tumor suppressor gene targets and induced apoptosis in melanoma cells harboring EZH2 Y646N in culture (PMID: 26304929).||26304929|
|EZH2 Y646N||follicular lymphoma||sensitive||EZH2 inhibitor||Tazemetostat||FDA approved - On Companion Diagnostic||Actionable||In a Phase II trial that supported FDA approval, Tazverik (tazemetostat) treatment was well-tolerated, resulted in a median progression-free survival of 11.1 months, objective response in 77% (33/43), and stable disease in 23% (10/43) of patients with relapsed or refractory follicular lymphoma, who had two or more prior therapies and harbored EZH2 mutations as detected by an approved test, including EZH2 Y646N (Blood (2019) 134 (Supplement_1):123; NCT01897571).||detail... detail... detail...|
|EZH2 Y646N||diffuse large B-cell lymphoma||sensitive||EED226||Preclinical - Cell culture||Actionable||In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).||28135235|
|EZH2 Y646N||lymphoma||sensitive||EZH2 inhibitor||Tazemetostat||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with Tazemetostat (EPZ-6438) inhibited proliferation and induced apoptosis in lymphoma cell lines harboring EZH2 Y646N in culture, and complete eradication of tumors in cell line xenograft models (PMID: 24563539).||24563539|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|